{"protocolSection":{"identificationModule":{"nctId":"NCT04596878","orgStudyIdInfo":{"id":"MVX0005"},"organization":{"fullName":"Minervax ApS","class":"OTHER"},"briefTitle":"Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV","officialTitle":"A Multi-centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Group B Streptococcus Vaccine (GBS-NN/NN2) in Women Who Are Pregnant and Living With HIV and Women Who Are Pregnant and do Not Have HIV"},"statusModule":{"statusVerifiedDate":"2026-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-11-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-05-18","type":"ACTUAL"},"completionDateStruct":{"date":"2023-05-11","type":"ACTUAL"},"studyFirstSubmitDate":"2020-10-14","studyFirstSubmitQcDate":"2020-10-20","studyFirstPostDateStruct":{"date":"2020-10-22","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-02-12","resultsFirstSubmitQcDate":"2026-06-16","resultsFirstPostDateStruct":{"date":"2026-07-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-06-16","lastUpdatePostDateStruct":{"date":"2026-07-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Minervax ApS","class":"OTHER"},"collaborators":[{"name":"European and Developing Countries Clinical Trials Partnership (EDCTP)","class":"OTHER_GOV"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A randomised, placebo-controlled, double-blind study to evaluate the safety, tolerability and immunogenicity of the GBS-NN/NN2 (Recombinant protein vaccine against Group B Streptococcus) vaccine in women living with HIV and women without HIV, and their newborn babies from vaccination up to delivery/birth. Mothers and babies will be followed up for 12 months post-delivery.","detailedDescription":"100 women who are pregnant and living with HIV will randomly receive two 0.5 mL (millilitre) intramuscular injections of GBS-NN/NN2 vaccine (80 women) or placebo (20 women).\n\n100 women who are pregnant and do not have HIV will randomly receive two 0.5 mL intramuscular injections of GBS-NN/NN2 vaccine (80 women) or placebo (20 women).\n\nParticipants will be screened at 24 to 28 weeks gestation (Days -14 to Day -1) and the groups will be dosed in parallel. The first dose of vaccine or placebo will be administered at Day 0 and the second dose will be administered 28±2 days later. Delivery is anticipated to be approximately 10 to 14 weeks after the first dose of vaccine.\n\nFor the analysis of the immune response, the placebo groups will be combined. For safety, the placebo groups will be analysed separately and will be combined for comparison with the potential vaccine groups."},"conditionsModule":{"conditions":["Group B Streptococcal Infection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Randomised, placebo controlled, double-blind, parallel group, multicentre study.","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":200,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"GBS-NN/NN2 in pregnant women living with HIV","type":"EXPERIMENTAL","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV","interventionNames":["Biological: GBS-NN/NN2"]},{"label":"Placebo Comparator in pregnant women living with HIV","type":"PLACEBO_COMPARATOR","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV","interventionNames":["Biological: Placebo"]},{"label":"GBS-NN/NN2 in pregnant women who do not have HIV","type":"EXPERIMENTAL","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV","interventionNames":["Biological: GBS-NN/NN2"]},{"label":"Placebo Comparator in pregnant women who do not have HIV","type":"PLACEBO_COMPARATOR","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"GBS-NN/NN2","description":"GBS-NN/NN2 bound to Alhydrogel as an adjuvant.","armGroupLabels":["GBS-NN/NN2 in pregnant women living with HIV","GBS-NN/NN2 in pregnant women who do not have HIV"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Normal Saline 0.9%","armGroupLabels":["Placebo Comparator in pregnant women living with HIV","Placebo Comparator in pregnant women who do not have HIV"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Treatment Emergent Adverse Events (TEAEs) in Maternal Participants","description":"Incidence of all TEAEs in maternal participants from first vaccination up to 28 days post-delivery.","timeFrame":"From first vaccination (26 to 30 weeks of gestation) up to 28 days post-delivery, up to 24 weeks"},{"measure":"Incidence of Adverse Events (AEs) in Newborn Babies","description":"Incidence of AEs in Newborn babies From birth to first visit after birth (visit 6).","timeFrame":"From birth to first visit after birth (28±4 days post-delivery)"},{"measure":"Number of Maternal Participants With Solicited Local AEs Within 7 Days After Each Study Vaccine Dose","description":"Number of maternal participants with solicited local AEs within 7 Days after each study vaccine dose, defined as: injection site redness, bruising, swelling, itching, pain and tenderness. Injection-site redness was graded based on measurements in centimeter (cm) as grade 0 (no visible redness), grade 1 (mild; 0-2 cm), grade 2 (moderate; 2.1-5 cm) or grade 3 (severe; \\> 5 cm). Swelling was graded as grade 0 (no swelling detected), grade 1 (palpable \"firmness\" only), grade 2 (0-4 cm) or grade 3 (\\> 4 cm). Pain at the injection site was rated on a visual analogue scale of 0 to 10, where 0 is no pain and 10 is extreme pain/worst possible pain. Bruising, itching and tenderness were categorised as either yes (present) or no (absent).","timeFrame":"For 7 days after each study vaccine dose (first vaccine administered at baseline, second vaccine administered 28 days post baseline)"},{"measure":"Number of Maternal Participants With Solicited Systemic AEs Within 7 Days After Each Study Vaccine Dose","description":"Number of maternal participants with solicited systemic AEs within 7 days after each study vaccine dose, defined as: headache, sore throat, \"flu-like\" symptoms, muscle aches, fever in the 72 hours post dose.","timeFrame":"For 7 days after each study vaccine dose (first vaccine administered at baseline, second vaccine administered 28 days post baseline)"},{"measure":"Gestational Age of Newborn Baby","description":"Gestational age of newborn baby","timeFrame":"At birth"},{"measure":"Weight of Newborn Baby","description":"Weight of newborn baby","timeFrame":"At birth"},{"measure":"Length of Newborn Baby","description":"Length of newborn baby","timeFrame":"At birth"},{"measure":"Head Circumference of Newborn Baby","description":"Head circumference of newborn baby","timeFrame":"At birth"},{"measure":"Apgar Score for Newborn Baby","description":"APGAR (Appearance, Pulse, Grimace, Activity, Respiration) score of newborn baby were measured at 1, 5 and 10 minutes. The APGAR score is a rapid clinical assessment tool used immediately after birth to evaluate a newborn's physical condition. It evaluates five criteria : Appearance (skin color), Pulse (heart rate), Grimace (Reflex irritability), Activity (muscle tone), Respiration (breathing effort), each category is scored 0, 1, or 2, where 2 indicates optimal function. Total score ranges from 0 to 10:\n\n7-10: Normal / Reassuring - baby adapting well 4-6: Moderately abnormal - may need assisted breathing or additional monitoring 0-3: Low - requires immediate resuscitation and urgent intervention","timeFrame":"At birth"},{"measure":"Transfer Rate (Baby/Mother) of IgG Antibody Concentrations","description":"For each of the specific IgG antibody concentrations, the transfer rate is defined as concentration in baby at birth/concentration in mother at delivery, expressed as a percentage.","timeFrame":"At delivery"}],"secondaryOutcomes":[{"measure":"Incidence of Significant Adverse Reactions in Mothers","description":"Incidence of significant adverse reactions in maternal participants","timeFrame":"From delivery to 6 months post-delivery"},{"measure":"Developmental Milestones of Babies","description":"Developmental milestones at 6 months were assessed using the Ages and Stages Questionnaire, Third Edition (ASQ-3), a validated developmental screening tool designed to evaluate early childhood development across 5 key domains: communication, gross motor, fine motor, problem solving, and personal-social. Each domain includes 6 items scored as Yes (10), Sometimes (5), or Not yet (0). Domain scores are calculated by summing item scores (range: 0-60 per domain); higher scores indicate better development. A total score (sum of all domains) may be calculated (range: 0-300), though interpretation relies primarily on domain scores. For each domain, the cut-offs are 29.65 for Communication, 22.25 for Gross Motor, 25.14 for Fine Motor, 27.72 for Problem Solving, and 25.34 for Personal-Social. Scores above these thresholds generally indicate development on schedule, while scores near the cutoff suggest monitoring, and scores below warrant additional assessment or referral.","timeFrame":"At 6 months"},{"measure":"Geometric Mean Antibody Concentration in Maternal Participants (4 Weeks)","description":"Geometric mean IgG antibody concentration in the maternal participants specific to Alpha Like Protein 1 (Alp1), Alpha Like Protein 2 (Alp2), Alpha Like Protein C (AlpC) and Rib protein (Rib).","timeFrame":"At 4 weeks post first injection and at 4 weeks post second injection"},{"measure":"Geometric Mean Antibody Concentration in Maternal Blood at 6 Months Post-delivery","description":"Geometric mean antibody concentration specific to Alp1, Alp2, AlpC and Rib in maternal blood at 6 months post-delivery","timeFrame":"6 months post-delivery"},{"measure":"Geometric Mean Antibody Concentration in Infant Blood at 1, 2, and 3 Months Post-delivery","description":"Geometric mean antibody concentration specific to Alp1, Alp2, AlpC and Rib in infant blood at 1, 2, and 3 months post-delivery","timeFrame":"At 1, 2, and 3 months post-delivery"},{"measure":"Geometric Mean Antibody Concentration in Newborns","description":"Geometric mean antibody concentration specific to Alp1, Alp2, AlpC and Rib in newborn blood within 48 hours of birth.","timeFrame":"Within 48 hours of birth."},{"measure":"Geometric Mean Antibody Concentration From Maternal Blood at Delivery","description":"Geometric mean antibody concentration specific to Alp1, Alp2, AlpC and Rib from maternal blood at delivery","timeFrame":"At delivery"},{"measure":"Geometric Mean Fold Increase in Antibody Concentration in Maternal Blood","description":"Geometric mean fold increase in IgG specific antibody concentration (Alp1, Alp2, AlpC and Rib) in maternal blood from baseline to 4 weeks after vaccination with the first and second dose.","timeFrame":"At 4 weeks post first injection and at 4 weeks post second injection"},{"measure":"Geometric Mean Fold Increase in Antibody Concentration in Maternal Blood","description":"Geometric mean fold increase in IgG specific antibody concentration (Alp1, Alp2, AlpC and Rib) in maternal blood from baseline to delivery.","timeFrame":"Baseline (Gestational Age 26 to 30 weeks) pre-vaccination to delivery, up to 24 weeks"},{"measure":"Proportion of Mothers Achieving Vaccine Specific IgG Antibody Concentrations","description":"Proportion of mothers achieving vaccine specific IgG antibody concentrations in maternal samples respectively, above pre-defined arbitrary thresholds (0.5, 1, 2 μg/mL).","timeFrame":"At delivery"},{"measure":"Proportion of Newborn Babies Achieving Vaccine Specific IgG Antibody Concentrations","description":"Proportion of newborn babies achieving vaccine specific IgG antibody concentrations above pre-defined arbitrary thresholds (0.5, 1, 2 μg/mL).","timeFrame":"At birth"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participants at least 18 years old and not older than 40 years of age.\n2. Pregnant women who are between 26 weeks and 30 weeks (inclusive) gestation on the planned day of vaccination with a singleton, uncomplicated pregnancy. Gestational age to be determined on the following hierarchal basis with guidance to the GAIA (Global Alignment of Immunisation Safety Assessment in pregnancy) criteria:\n\n   1. ultrasound estimate of gestational age,\n   2. date of last menstrual period\n   3. fundal height\n3. HIV status to be based on rapid, confirmatory test, unless a documented test of the participant being sero-positive for HIV and history documented in the notes.\n4. Women living with HIV, HIV viral load \\<1000, on antiretroviral therapy for at least 3 months prior to screening and clinically well.\n5. Expected to be available for the scheduled clinic visits for the duration of the study, agree to be contacted by telephone during study participation, and is willing to give parental consent for her infant to participate in the study\n\nExclusion Criteria:\n\n1. Women who are hepatitis B surface (HBSAg) and/or hepatitis C (HCV) positive\n2. Women who test positive for syphilis as per standard testing\n3. Women knowingly carrying, at screening, a malformed or genetically abnormal foetus based on ultrasound\n4. Women who have experienced a previous stillbirth prior to going into labour\n5. Women with placenta previa\n6. Women with documented chronic or pregnancy induced hypertension at screening\n7. Women with 1+ protein in urine and hypertension defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) at ≥20 weeks of gestation in a woman with a previously normal blood pressure\n8. Women with \\>1+ of protein in urine (regardless of blood pressure)\n9. Women with gestational, type 1 or type 2 diabetes.\n10. Women with glycosuria on dipstick\n11. Women known to be allergic to any components of the vaccine, known to be allergic to aluminium or having had an allergic reaction to any previous vaccination.\n12. Women with history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, psychiatric, autoimmune disease, cognitive disorder or current infection and significant illness 4 weeks prior to randomization.\n13. Women with current or history of drug or alcohol abuse within the last two years.\n14. Women who have received a vaccine within 28 days of receiving the first dose of GBS NN/NN2 or placebo or who expect to require vaccination during the course of the study. (Vaccines recommended for administration during pregnancy e.g. tetanus toxoid, pertussis and influenza are permitted. Administration of concurrent vaccines must not be within 7 days of investigational vaccine.)\n15. Women who have a fever (axillary temperature \\>37.9°C) on the day of dosing or have had an acute infection in the 7 days before dosing.\n16. Women who have any bleeding disorders that prolong the bleeding time.\n17. Women who are receiving immunosuppressive medication, including systemic steroids (inhaled and topical steroids are acceptable).\n18. Women who have received blood or blood products and/or plasma derivatives or any immunoglobulin preparations in 12 weeks preceding screening.\n19. Women with severe anaemia, haemoglobin \\< 9g/dL (90 g/L) as per Sheffield grading system ( \\> Grade 1)\n20. Women who are currently breast feeding\n21. Women who are part of the study personnel or a close family member of study personnel.\n22. Women who in the opinion of the investigator are not suitable to participate in the study.\n23. Concurrent participation in another clinical trial during which subject will be exposed to an investigational product.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Cornelia Oostvogels","affiliation":"Minervax ApS","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Empilweni Services and Research Unit (ESRU), Rahima Moosa Mother and Child Hospital","city":"Johannesburg","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"University of the Witwatersrand, Johannesburg (Respiratory and Meningeal Pathogens Research unit)","city":"Johannesburg","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"MUJHU Research Collaboration/MUJHU Care Ltd, Kawempe National Referral Hospital","city":"Kawempe","country":"Uganda","geoPoint":{"lat":0.37812,"lon":32.55774}}]},"referencesModule":{"references":[{"pmid":"38190492","type":"DERIVED","citation":"Galiza EP, Khalil A, Heath PT. Update on Vaccines in Antenatal Care. Pediatr Infect Dis J. 2024 Feb 1;43(2):e60-e62. doi: 10.1097/INF.0000000000004183. Epub 2023 Dec 27. No abstract available."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"FG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant"},{"id":"FG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV Placebo: Normal Saline 0.9%"},{"id":"FG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"80"},{"groupId":"FG001","numSubjects":"80"},{"groupId":"FG002","numSubjects":"20"},{"groupId":"FG003","numSubjects":"20"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"71"},{"groupId":"FG001","numSubjects":"69"},{"groupId":"FG002","numSubjects":"19"},{"groupId":"FG003","numSubjects":"16"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Death of a baby","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Imprisonment","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Unable to come for follow-ups due to relocation or new job","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"BG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"BG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"BG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"200"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"200"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31.4","spread":"4.8"},{"groupId":"BG001","value":"26.4","spread":"5.4"},{"groupId":"BG002","value":"31.0","spread":"5.5"},{"groupId":"BG003","value":"26.3","spread":"5.3"},{"groupId":"BG004","value":"28.9","spread":"5.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"200"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"199"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"78"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"198"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"South Africa","categories":[{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"150"}]}]},{"title":"Uganda","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"50"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Treatment Emergent Adverse Events (TEAEs) in Maternal Participants","description":"Incidence of all TEAEs in maternal participants from first vaccination up to 28 days post-delivery.","populationDescription":"Safety Analysis Set (SAF)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Adverse Events","timeFrame":"From first vaccination (26 to 30 weeks of gestation) up to 28 days post-delivery, up to 24 weeks","groups":[{"id":"OG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"223"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"48"}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Events (AEs) in Newborn Babies","description":"Incidence of AEs in Newborn babies From birth to first visit after birth (visit 6).","populationDescription":"Baby Safety Analysis Set (BSA)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Adverse Events","timeFrame":"From birth to first visit after birth (28±4 days post-delivery)","groups":[{"id":"OG000","title":"Babies From Women Vaccinated With GBS-NN/NN2 Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart.\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"Babies From Women Vaccinated With GBS-NN/NN2 Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator: Babies From Women Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator: Babies From Women Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"191"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"54"}]}]}]},{"type":"PRIMARY","title":"Number of Maternal Participants With Solicited Local AEs Within 7 Days After Each Study Vaccine Dose","description":"Number of maternal participants with solicited local AEs within 7 Days after each study vaccine dose, defined as: injection site redness, bruising, swelling, itching, pain and tenderness. Injection-site redness was graded based on measurements in centimeter (cm) as grade 0 (no visible redness), grade 1 (mild; 0-2 cm), grade 2 (moderate; 2.1-5 cm) or grade 3 (severe; \\> 5 cm). Swelling was graded as grade 0 (no swelling detected), grade 1 (palpable \"firmness\" only), grade 2 (0-4 cm) or grade 3 (\\> 4 cm). Pain at the injection site was rated on a visual analogue scale of 0 to 10, where 0 is no pain and 10 is extreme pain/worst possible pain. Bruising, itching and tenderness were categorised as either yes (present) or no (absent).","populationDescription":"SAF","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"For 7 days after each study vaccine dose (first vaccine administered at baseline, second vaccine administered 28 days post baseline)","groups":[{"id":"OG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"classes":[{"title":"Post-Dose 1 : Bruising - No","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}]},{"title":"Post-Dose 1 : Bruising - Yes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-Dose 1 : Itching - No","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"17"}]}]},{"title":"Post-Dose 1 : Itching - Yes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"}]}]},{"title":"Post-Dose 1 : Redness - 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"16"}]}]},{"title":"Post-Dose 1 : Redness - 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]}]},{"title":"Post-Dose 1 : Redness - 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-Dose 1 : Redness - 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 1 : Swelling - 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"13"}]}]},{"title":"Post-Dose 1 : Swelling - 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"}]}]},{"title":"Post-Dose 1 : Swelling - 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]},{"title":"Post-Dose 1 : Swelling - 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 1 : Tenderness - No","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]},{"title":"Post-Dose 1 : Tenderness - Yes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"18"}]}]},{"title":"Post-Dose 1 : Pain - 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"11"}]}]},{"title":"Post-Dose 1 : Pain - 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"}]}]},{"title":"Post-Dose 1 : Pain - 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}]},{"title":"Post-Dose 1 : Pain - 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]},{"title":"Post-Dose 1 : Pain - 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-Dose 1 : Pain - 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 1 : Pain - 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 1 : Pain - 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 1 : Pain - 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 1 : Pain - 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 1 : Pain - 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 2 : Bruising - No","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"18"}]}]},{"title":"Post-Dose 2 : Bruising - Yes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]},{"title":"Post-Dose 2 : Itching - No","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"19"}]}]},{"title":"Post-Dose 2 : Itching - Yes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]},{"title":"Post-Dose 2 : Redness - 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"19"}]}]},{"title":"Post-Dose 2 : Redness - 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 2 : Redness - 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-Dose 2 : Redness - 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 2 : Swelling - 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"15"}]}]},{"title":"Post-Dose 2 : Swelling - 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}]}]},{"title":"Post-Dose 2 : Swelling - 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-Dose 2 : Swelling - 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 2 : Tenderness - No","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 2 : Tenderness - Yes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"20"}]}]},{"title":"Post-Dose 2 : Pain - 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"16"}]}]},{"title":"Post-Dose 2 : Pain - 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-Dose 2 : Pain - 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-Dose 2 : Pain - 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-Dose 2 : Pain - 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-Dose 2 : Pain - 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 2 : Pain - 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 2 : Pain - 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 2 : Pain - 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 2 : Pain - 9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-Dose 2 : Pain - 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Maternal Participants With Solicited Systemic AEs Within 7 Days After Each Study Vaccine Dose","description":"Number of maternal participants with solicited systemic AEs within 7 days after each study vaccine dose, defined as: headache, sore throat, \"flu-like\" symptoms, muscle aches, fever in the 72 hours post dose.","populationDescription":"SAF","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"For 7 days after each study vaccine dose (first vaccine administered at baseline, second vaccine administered 28 days post baseline)","groups":[{"id":"OG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"classes":[{"title":"Post-dose 1 : Headache - Mild","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"}]}]},{"title":"Post-dose 1 : Headache - Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 1 : Headache - Severe","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 1 : Sore throat - Mild","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]}]},{"title":"Post-dose 1 : Sore throat - Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 1 : Sore throat - Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 1 : Flu-like symptoms - Mild","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"}]}]},{"title":"Post-dose 1 : Flu-like symptoms - Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-dose 1 : Flu-like symptoms - Severe","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 1 : Muscle aches - Mild","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"}]}]},{"title":"Post-dose 1 : Muscle aches - Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 1 : Muscle aches - Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 1 : Fever ≥ 37.9°C","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 2 : Headache - Mild","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-dose 2 : Headache - Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}]},{"title":"Post-dose 2 : Headache - Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-dose 2 : Sore throat - Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-dose 2 : Sore throat - Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]},{"title":"Post-dose 2 : Sore throat - Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 2 : Flu-like symptoms - Mild","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"}]}]},{"title":"Post-dose 2 : Flu-like symptoms - Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Post-dose 2 : Flu-like symptoms - Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 2 : Muscle aches - Mild","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"}]}]},{"title":"Post-dose 2 : Muscle aches - Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 2 : Muscle aches - Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Post-dose 2 : Fever ≥ 37.9°C","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"PRIMARY","title":"Gestational Age of Newborn Baby","description":"Gestational age of newborn baby","populationDescription":"Baby Safety Analysis Set","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Weeks","timeFrame":"At birth","groups":[{"id":"OG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":"2.0"},{"groupId":"OG001","value":"39.1","spread":"2.1"},{"groupId":"OG002","value":"37.9","spread":"3.7"},{"groupId":"OG003","value":"39.0","spread":"2.0"}]}]}]},{"type":"PRIMARY","title":"Weight of Newborn Baby","description":"Weight of newborn baby","populationDescription":"Baby Safety Analysis Set","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Kg","timeFrame":"At birth","groups":[{"id":"OG000","title":"Babies From Women Vaccinated With GBS-NN/NN2 Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart.\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"Babies From Women Vaccinated With GBS-NN/NN2 Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator: Babies From Women Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator: Babies From Women Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"0.6"},{"groupId":"OG001","value":"3.0","spread":"0.5"},{"groupId":"OG002","value":"2.7","spread":"0.6"},{"groupId":"OG003","value":"3.2","spread":"0.6"}]}]}]},{"type":"PRIMARY","title":"Length of Newborn Baby","description":"Length of newborn baby","populationDescription":"Baby Safety Analysis Set","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"cm","timeFrame":"At birth","groups":[{"id":"OG000","title":"Babies From Women Vaccinated With GBS-NN/NN2 Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart.\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"Babies From Women Vaccinated With GBS-NN/NN2 Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator: Babies From Women Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator: Babies From Women Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.6","spread":"3.4"},{"groupId":"OG001","value":"49.0","spread":"2.3"},{"groupId":"OG002","value":"47.8","spread":"4.9"},{"groupId":"OG003","value":"50.8","spread":"3.9"}]}]}]},{"type":"PRIMARY","title":"Head Circumference of Newborn Baby","description":"Head circumference of newborn baby","populationDescription":"Baby Safety Analysis Set","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"cm","timeFrame":"At birth","groups":[{"id":"OG000","title":"Babies From Women Vaccinated With GBS-NN/NN2 Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart.\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"Babies From Women Vaccinated With GBS-NN/NN2 Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator: Babies From Women Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator: Babies From Women Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.2","spread":"1.6"},{"groupId":"OG001","value":"34.2","spread":"1.4"},{"groupId":"OG002","value":"32.6","spread":"3.9"},{"groupId":"OG003","value":"34.9","spread":"2.3"}]}]}]},{"type":"PRIMARY","title":"Apgar Score for Newborn Baby","description":"APGAR (Appearance, Pulse, Grimace, Activity, Respiration) score of newborn baby were measured at 1, 5 and 10 minutes. The APGAR score is a rapid clinical assessment tool used immediately after birth to evaluate a newborn's physical condition. It evaluates five criteria : Appearance (skin color), Pulse (heart rate), Grimace (Reflex irritability), Activity (muscle tone), Respiration (breathing effort), each category is scored 0, 1, or 2, where 2 indicates optimal function. Total score ranges from 0 to 10:\n\n7-10: Normal / Reassuring - baby adapting well 4-6: Moderately abnormal - may need assisted breathing or additional monitoring 0-3: Low - requires immediate resuscitation and urgent intervention","populationDescription":"Baby Safety Analysis Set; APGAR score at 10 minutes were evaluated in babies with APGAR score \\< 10 at 1 and 5 minutes.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"At birth","groups":[{"id":"OG000","title":"Babies From Women Vaccinated With GBS-NN/NN2 Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart.\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"Babies From Women Vaccinated With GBS-NN/NN2 Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator: Babies From Women Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator: Babies From Women Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"classes":[{"title":"1 minute","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"1.1"},{"groupId":"OG001","value":"8.6","spread":"1.0"},{"groupId":"OG002","value":"8.0","spread":"2.1"},{"groupId":"OG003","value":"8.8","spread":"0.6"}]}]},{"title":"5 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"0.4"},{"groupId":"OG001","value":"9.7","spread":"0.8"},{"groupId":"OG002","value":"9.6","spread":"0.8"},{"groupId":"OG003","value":"9.8","spread":"0.5"}]}]},{"title":"10 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"0.3"},{"groupId":"OG001","value":"9.5","spread":"1.0"},{"groupId":"OG002","value":"9.0","spread":"1.0"},{"groupId":"OG003","value":"10.0","spread":"0"}]}]}]},{"type":"PRIMARY","title":"Transfer Rate (Baby/Mother) of IgG Antibody Concentrations","description":"For each of the specific IgG antibody concentrations, the transfer rate is defined as concentration in baby at birth/concentration in mother at delivery, expressed as a percentage.","populationDescription":"Baby Immunogenicity Set","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"percentage","timeFrame":"At delivery","groups":[{"id":"OG000","title":"Babies From Women Vaccinated With GBS-NN/NN2 Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart.\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"Babies From Women Vaccinated With GBS-NN/NN2 Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator: Babies From Women Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV"},{"id":"OG003","title":"Placebo Comparator: Babies From Women Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"}]}],"classes":[{"title":"RibN","categories":[{"measurements":[{"groupId":"OG000","value":"87.5","lowerLimit":"56.1","upperLimit":"110.6"},{"groupId":"OG001","value":"122.1","lowerLimit":"56.7","upperLimit":"156.0"},{"groupId":"OG002","value":"37.2","lowerLimit":"33.0","upperLimit":"57.6"},{"groupId":"OG003","value":"14.5","lowerLimit":"5.1","upperLimit":"89.1"}]}]},{"title":"Alp1N","categories":[{"measurements":[{"groupId":"OG000","value":"80.5","lowerLimit":"56.2","upperLimit":"94.7"},{"groupId":"OG001","value":"114.4","lowerLimit":"55.5","upperLimit":"149.4"},{"groupId":"OG002","value":"34.1","lowerLimit":"27.5","upperLimit":"47.3"},{"groupId":"OG003","value":"36.1","lowerLimit":"3.6","upperLimit":"73.2"}]}]},{"title":"Alp2N","categories":[{"measurements":[{"groupId":"OG000","value":"56.4","lowerLimit":"30.2","upperLimit":"89.7"},{"groupId":"OG001","value":"110.5","lowerLimit":"65.7","upperLimit":"138.8"},{"groupId":"OG002","value":"34.7","lowerLimit":"19.8","upperLimit":"54.2"},{"groupId":"OG003","value":"50.3","lowerLimit":"6.7","upperLimit":"100.0"}]}]},{"title":"AlpCN","categories":[{"measurements":[{"groupId":"OG000","value":"69.8","lowerLimit":"37.7","upperLimit":"100.8"},{"groupId":"OG001","value":"119.0","lowerLimit":"4.9","upperLimit":"155.5"},{"groupId":"OG002","value":"49.9","lowerLimit":"30.0","upperLimit":"58.1"},{"groupId":"OG003","value":"10.6","lowerLimit":"5.6","upperLimit":"54.9"}]}]}]},{"type":"SECONDARY","title":"Incidence of Significant Adverse Reactions in Mothers","description":"Incidence of significant adverse reactions in maternal participants","populationDescription":"Safety Analysis Set (SAF)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Adverse Events","timeFrame":"From delivery to 6 months post-delivery","groups":[{"id":"OG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Developmental Milestones of Babies","description":"Developmental milestones at 6 months were assessed using the Ages and Stages Questionnaire, Third Edition (ASQ-3), a validated developmental screening tool designed to evaluate early childhood development across 5 key domains: communication, gross motor, fine motor, problem solving, and personal-social. Each domain includes 6 items scored as Yes (10), Sometimes (5), or Not yet (0). Domain scores are calculated by summing item scores (range: 0-60 per domain); higher scores indicate better development. A total score (sum of all domains) may be calculated (range: 0-300), though interpretation relies primarily on domain scores. For each domain, the cut-offs are 29.65 for Communication, 22.25 for Gross Motor, 25.14 for Fine Motor, 27.72 for Problem Solving, and 25.34 for Personal-Social. Scores above these thresholds generally indicate development on schedule, while scores near the cutoff suggest monitoring, and scores below warrant additional assessment or referral.","populationDescription":"Baby Safety Analysis Set","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"At 6 months","groups":[{"id":"OG000","title":"Babies From Women Vaccinated With GBS-NN/NN2 Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart.\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"Babies From Women Vaccinated With GBS-NN/NN2 Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator: Babies From Women Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator: Babies From Women Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"16"}]}],"classes":[{"title":"Communication Score","categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":"6.2"},{"groupId":"OG001","value":"51.9","spread":"8.9"},{"groupId":"OG002","value":"52.8","spread":"7.3"},{"groupId":"OG003","value":"54.7","spread":"6.9"}]}]},{"title":"Fine Motor Score","categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":"7.0"},{"groupId":"OG001","value":"51.7","spread":"10.4"},{"groupId":"OG002","value":"56.7","spread":"5.7"},{"groupId":"OG003","value":"54.1","spread":"7.4"}]}]},{"title":"Gross Motor Score","categories":[{"measurements":[{"groupId":"OG000","value":"49.9","spread":"7.9"},{"groupId":"OG001","value":"46.8","spread":"11.3"},{"groupId":"OG002","value":"50.0","spread":"7.5"},{"groupId":"OG003","value":"50.0","spread":"8.0"}]}]},{"title":"Problem Solving Score","categories":[{"measurements":[{"groupId":"OG000","value":"56.7","spread":"5.6"},{"groupId":"OG001","value":"53.5","spread":"7.6"},{"groupId":"OG002","value":"54.4","spread":"5.9"},{"groupId":"OG003","value":"55.3","spread":"6.9"}]}]},{"title":"Personal Social Score","categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":"9.1"},{"groupId":"OG001","value":"48.7","spread":"11.6"},{"groupId":"OG002","value":"52.6","spread":"6.7"},{"groupId":"OG003","value":"52.8","spread":"11.8"}]}]},{"title":"Total Domain Score","categories":[{"measurements":[{"groupId":"OG000","value":"268.1","spread":"22.9"},{"groupId":"OG001","value":"252.5","spread":"36.9"},{"groupId":"OG002","value":"266.5","spread":"19.5"},{"groupId":"OG003","value":"266.9","spread":"25.6"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Concentration in Maternal Participants (4 Weeks)","description":"Geometric mean IgG antibody concentration in the maternal participants specific to Alpha Like Protein 1 (Alp1), Alpha Like Protein 2 (Alp2), Alpha Like Protein C (AlpC) and Rib protein (Rib).","populationDescription":"Maternal Immunogenicity Set","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"µg/mL","timeFrame":"At 4 weeks post first injection and at 4 weeks post second injection","groups":[{"id":"OG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"15"}]}],"classes":[{"title":"Alp1 - Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"147.8"},{"groupId":"OG001","value":"0.2","spread":"106.0"},{"groupId":"OG002","value":"0.2","spread":"196.1"},{"groupId":"OG003","value":"0.2","spread":"133.9"}]}]},{"title":"Alp1 - 4 weeks post 1st injection","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"229.4"},{"groupId":"OG001","value":"5.9","spread":"375.0"},{"groupId":"OG002","value":"0.2","spread":"200.2"},{"groupId":"OG003","value":"0.2","spread":"125.7"}]}]},{"title":"Alp1 - 4 weeks post 2nd injection","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"138.4"},{"groupId":"OG001","value":"9.8","spread":"178.9"},{"groupId":"OG002","value":"0.2","spread":"173.4"},{"groupId":"OG003","value":"0.3","spread":"384.4"}]}]},{"title":"Alp2 - Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"166.9"},{"groupId":"OG001","value":"0.1","spread":"130.3"},{"groupId":"OG002","value":"0.1","spread":"234.8"},{"groupId":"OG003","value":"0.1","spread":"207.9"}]}]},{"title":"Alp2 - 4 weeks post 1st injection","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"212.0"},{"groupId":"OG001","value":"4.8","spread":"452.7"},{"groupId":"OG002","value":"0.1","spread":"288.9"},{"groupId":"OG003","value":"0.1","spread":"155.9"}]}]},{"title":"Alp2 - 4 weeks post 2nd injection","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"137.4"},{"groupId":"OG001","value":"7.0","spread":"177.2"},{"groupId":"OG002","value":"0.1","spread":"239.9"},{"groupId":"OG003","value":"0.1","spread":"829.1"}]}]},{"title":"AlpC - Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"114.7"},{"groupId":"OG001","value":"0.2","spread":"101.1"},{"groupId":"OG002","value":"0.2","spread":"170.9"},{"groupId":"OG003","value":"0.2","spread":"115.8"}]}]},{"title":"AlpC - 4 weeks post 1st injection","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"243.8"},{"groupId":"OG001","value":"7.6","spread":"411.2"},{"groupId":"OG002","value":"0.2","spread":"161.1"},{"groupId":"OG003","value":"0.2","spread":"141.0"}]}]},{"title":"AlpC - 4 weeks post 2nd injection","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"210.3"},{"groupId":"OG001","value":"10.0","spread":"204.4"},{"groupId":"OG002","value":"0.2","spread":"151.8"},{"groupId":"OG003","value":"0.2","spread":"298.3"}]}]},{"title":"Rib - Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"150.4"},{"groupId":"OG001","value":"0.1","spread":"104.9"},{"groupId":"OG002","value":"0.1","spread":"86.0"},{"groupId":"OG003","value":"0.1","spread":"114.9"}]}]},{"title":"Rib - 4 weeks post 1st injection","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"284.8"},{"groupId":"OG001","value":"3.3","spread":"477.0"},{"groupId":"OG002","value":"0.1","spread":"101.5"},{"groupId":"OG003","value":"0.1","spread":"115.0"}]}]},{"title":"Rib - 4 weeks post 2nd injection","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"251.3"},{"groupId":"OG001","value":"4.6","spread":"263.2"},{"groupId":"OG002","value":"0.1","spread":"112.3"},{"groupId":"OG003","value":"0.1","spread":"255.1"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Concentration in Maternal Blood at 6 Months Post-delivery","description":"Geometric mean antibody concentration specific to Alp1, Alp2, AlpC and Rib in maternal blood at 6 months post-delivery","populationDescription":"MIG","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ug/mL","timeFrame":"6 months post-delivery","groups":[{"id":"OG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"15"}]}],"classes":[{"title":"Alp1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"199.1"},{"groupId":"OG001","value":"4.1","spread":"187.9"},{"groupId":"OG002","value":"0.3","spread":"173.0"},{"groupId":"OG003","value":"0.2","spread":"149.3"}]}]},{"title":"Alp2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"201.3"},{"groupId":"OG001","value":"3.2","spread":"230.9"},{"groupId":"OG002","value":"0.1","spread":"217.8"},{"groupId":"OG003","value":"0.1","spread":"146.6"}]}]},{"title":"AlpC","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"240.3"},{"groupId":"OG001","value":"4.1","spread":"222.2"},{"groupId":"OG002","value":"0.2","spread":"138.2"},{"groupId":"OG003","value":"0.2","spread":"99.2"}]}]},{"title":"Rib","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"255.3"},{"groupId":"OG001","value":"1.8","spread":"223.3"},{"groupId":"OG002","value":"0.2","spread":"72.5"},{"groupId":"OG003","value":"0.1","spread":"78.4"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Concentration in Infant Blood at 1, 2, and 3 Months Post-delivery","description":"Geometric mean antibody concentration specific to Alp1, Alp2, AlpC and Rib in infant blood at 1, 2, and 3 months post-delivery","populationDescription":"BIG population","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ug/mL","timeFrame":"At 1, 2, and 3 months post-delivery","groups":[{"id":"OG000","title":"Babies From Women Vaccinated With GBS-NN/NN2 Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart.\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"Babies From Women Vaccinated With GBS-NN/NN2 Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator: Babies From Women Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator: Babies From Women Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"}]}],"classes":[{"title":"Alp1 - 1 month","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"193.7"},{"groupId":"OG001","value":"1.8","spread":"1226.2"},{"groupId":"OG002","value":"0.1","spread":"909.5"},{"groupId":"OG003","value":"0.0","spread":"379.3"}]}]},{"title":"Alp1 - 2 months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"236.0"},{"groupId":"OG001","value":"0.5","spread":"2880.4"},{"groupId":"OG002","value":"0.0","spread":"154.8"},{"groupId":"OG003","value":"0.1","spread":"329.9"}]}]},{"title":"Alp1 - 3 months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"122.3"},{"groupId":"OG001","value":"0.8","spread":"3108.7"},{"groupId":"OG002","value":"0.2","spread":"27.2"},{"groupId":"OG003","value":"0.1","spread":"89.1"}]}]},{"title":"Alp2 - 1 month","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"285.8"},{"groupId":"OG001","value":"1.4","spread":"1085.8"},{"groupId":"OG002","value":"0.0","spread":"1175.7"},{"groupId":"OG003","value":"0.0","spread":"163.2"}]}]},{"title":"Alp2 - 2 months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"323.5"},{"groupId":"OG001","value":"0.5","spread":"2171.6"},{"groupId":"OG002","value":"0.0","spread":"178.3"},{"groupId":"OG003","value":"0.1","spread":"199.9"}]}]},{"title":"Alp2 - 3 months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"111.7"},{"groupId":"OG001","value":"1.1","spread":"983.2"},{"groupId":"OG002","value":"0.1","spread":"58.3"},{"groupId":"OG003","value":"0.0","spread":"115.9"}]}]},{"title":"AlpC - 1 month","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"311.1"},{"groupId":"OG001","value":"1.7","spread":"1398.8"},{"groupId":"OG002","value":"0.0","spread":"59.5"},{"groupId":"OG003","value":"0.0","spread":"204.9"}]}]},{"title":"AlpC - 2 months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"289.3"},{"groupId":"OG001","value":"0.6","spread":"2852.9"},{"groupId":"OG002","value":"0.0","spread":"66.0"},{"groupId":"OG003","value":"0.1","spread":"295.2"}]}]},{"title":"AlpC - 3 months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"455.9"},{"groupId":"OG001","value":"1.0","spread":"4809.1"},{"groupId":"OG002","value":"0.1","spread":"6.9"},{"groupId":"OG003","value":"0.1","spread":"85.9"}]}]},{"title":"Rib - 1 month","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"280.6"},{"groupId":"OG001","value":"1.4","spread":"397.6"},{"groupId":"OG002","value":"0.1","spread":"3373.8"},{"groupId":"OG003","value":"0.0","spread":"254.0"}]}]},{"title":"Rib - 2 months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"205.5"},{"groupId":"OG001","value":"1.1","spread":"640.2"},{"groupId":"OG002","value":"0.1","spread":"165.5"},{"groupId":"OG003","value":"0.0","spread":"238.9"}]}]},{"title":"Rib - 3 months","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"340.3"},{"groupId":"OG001","value":"0.6","spread":"859.4"},{"groupId":"OG002","value":"0.1","spread":"42.8"},{"groupId":"OG003","value":"0.1","spread":"108.3"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Concentration in Newborns","description":"Geometric mean antibody concentration specific to Alp1, Alp2, AlpC and Rib in newborn blood within 48 hours of birth.","populationDescription":"Baby Immunogenicity Set","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"µg/ml","timeFrame":"Within 48 hours of birth.","groups":[{"id":"OG000","title":"Babies From Women Vaccinated With GBS-NN/NN2 Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart.\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"Babies From Women Vaccinated With GBS-NN/NN2 Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator: Babies From Women Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator: Babies From Women Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"}]}],"classes":[{"title":"Alp1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"221.9"},{"groupId":"OG001","value":"2.1","spread":"3054.4"},{"groupId":"OG002","value":"0.0","spread":"107.4"},{"groupId":"OG003","value":"0.0","spread":"596.2"}]}]},{"title":"Alp2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"325.3"},{"groupId":"OG001","value":"1.7","spread":"1893.1"},{"groupId":"OG002","value":"0.0","spread":"81.5"},{"groupId":"OG003","value":"0.0","spread":"184.5"}]}]},{"title":"AlpC","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"443.9"},{"groupId":"OG001","value":"1.9","spread":"3975.3"},{"groupId":"OG002","value":"0.1","spread":"96.6"},{"groupId":"OG003","value":"0.0","spread":"518.7"}]}]},{"title":"Rib","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"419.1"},{"groupId":"OG001","value":"1.4","spread":"1272.7"},{"groupId":"OG002","value":"0.1","spread":"227.1"},{"groupId":"OG003","value":"0.0","spread":"525.0"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Concentration From Maternal Blood at Delivery","description":"Geometric mean antibody concentration specific to Alp1, Alp2, AlpC and Rib from maternal blood at delivery","populationDescription":"Maternal Immunogenicity Set","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"µg/mL","timeFrame":"At delivery","groups":[{"id":"OG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"15"}]}],"classes":[{"title":"Alp1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"194.4"},{"groupId":"OG001","value":"7.3","spread":"138.3"},{"groupId":"OG002","value":"0.2","spread":"167.9"},{"groupId":"OG003","value":"0.2","spread":"123.5"}]}]},{"title":"Alp2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"168.9"},{"groupId":"OG001","value":"5.5","spread":"187.9"},{"groupId":"OG002","value":"0.1","spread":"199.3"},{"groupId":"OG003","value":"0.1","spread":"146.3"}]}]},{"title":"AlpC","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"207.7"},{"groupId":"OG001","value":"8.6","spread":"183.8"},{"groupId":"OG002","value":"0.2","spread":"134.2"},{"groupId":"OG003","value":"0.2","spread":"146.8"}]}]},{"title":"Rib","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"343.9"},{"groupId":"OG001","value":"3.2","spread":"285.9"},{"groupId":"OG002","value":"0.1","spread":"80.3"},{"groupId":"OG003","value":"0.1","spread":"112.4"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Increase in Antibody Concentration in Maternal Blood","description":"Geometric mean fold increase in IgG specific antibody concentration (Alp1, Alp2, AlpC and Rib) in maternal blood from baseline to 4 weeks after vaccination with the first and second dose.","populationDescription":"Maternal Immunogenicity Set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric mean fold increase","timeFrame":"At 4 weeks post first injection and at 4 weeks post second injection","groups":[{"id":"OG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"15"}]}],"classes":[{"title":"Alp1N - 4 weeks post-Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"35.6","lowerLimit":"24.9","upperLimit":"50.9"},{"groupId":"OG001","value":"32.9","lowerLimit":"22.5","upperLimit":"48.0"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.8","upperLimit":"1.3"},{"groupId":"OG003","value":"1.0","lowerLimit":"0.9","upperLimit":"1.1"}]}]},{"title":"Alp1N - 4 weeks post-Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"47.6","lowerLimit":"34.9","upperLimit":"65.0"},{"groupId":"OG001","value":"59.1","lowerLimit":"42.9","upperLimit":"81.5"},{"groupId":"OG002","value":"0.9","lowerLimit":"0.7","upperLimit":"1.2"},{"groupId":"OG003","value":"1.3","lowerLimit":"0.5","upperLimit":"3.4"}]}]},{"title":"Alp2N - 4 weeks post-Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"41.0","lowerLimit":"27.4","upperLimit":"61.4"},{"groupId":"OG001","value":"43.9","lowerLimit":"30.5","upperLimit":"63.2"},{"groupId":"OG002","value":"0.8","lowerLimit":"0.6","upperLimit":"1.0"},{"groupId":"OG003","value":"1.1","lowerLimit":"0.9","upperLimit":"1.3"}]}]},{"title":"Alp2N - 4 weeks post-Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"64.0","lowerLimit":"41.5","upperLimit":"98.8"},{"groupId":"OG001","value":"73.8","lowerLimit":"54.4","upperLimit":"100.2"},{"groupId":"OG002","value":"0.9","lowerLimit":"0.7","upperLimit":"1.2"},{"groupId":"OG003","value":"1.6","lowerLimit":"0.4","upperLimit":"5.6"}]}]},{"title":"AlpCN - 4 weeks post-Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"49.5","lowerLimit":"34.2","upperLimit":"71.7"},{"groupId":"OG001","value":"39.1","lowerLimit":"26.4","upperLimit":"57.8"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.8","upperLimit":"1.2"},{"groupId":"OG003","value":"1.0","lowerLimit":"0.8","upperLimit":"1.2"}]}]},{"title":"AlpCN - 4 weeks post-Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"65.1","lowerLimit":"47.9","upperLimit":"88.4"},{"groupId":"OG001","value":"55.9","lowerLimit":"41.5","upperLimit":"75.2"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.8","upperLimit":"1.3"},{"groupId":"OG003","value":"1.1","lowerLimit":"0.6","upperLimit":"1.9"}]}]},{"title":"RibN - 4 weeks post-Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"28.5","lowerLimit":"19.6","upperLimit":"41.3"},{"groupId":"OG001","value":"31.2","lowerLimit":"20.7","upperLimit":"47.1"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.8","upperLimit":"1.3"},{"groupId":"OG003","value":"1.0","lowerLimit":"0.9","upperLimit":"1.1"}]}]},{"title":"RibN - 4 weeks post-Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"27.7","lowerLimit":"17.3","upperLimit":"44.4"},{"groupId":"OG001","value":"41.4","lowerLimit":"29.3","upperLimit":"58.5"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.7","upperLimit":"1.3"},{"groupId":"OG003","value":"1.1","lowerLimit":"0.6","upperLimit":"1.9"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Increase in Antibody Concentration in Maternal Blood","description":"Geometric mean fold increase in IgG specific antibody concentration (Alp1, Alp2, AlpC and Rib) in maternal blood from baseline to delivery.","populationDescription":"Maternal Immunogenicity Set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric mean fold increase","timeFrame":"Baseline (Gestational Age 26 to 30 weeks) pre-vaccination to delivery, up to 24 weeks","groups":[{"id":"OG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"15"}]}],"classes":[{"title":"Alp1N","categories":[{"measurements":[{"groupId":"OG000","value":"37.3","lowerLimit":"27.7","upperLimit":"50.0"},{"groupId":"OG001","value":"42.3","lowerLimit":"31.9","upperLimit":"56.0"},{"groupId":"OG002","value":"0.8","lowerLimit":"0.7","upperLimit":"1.0"},{"groupId":"OG003","value":"0.9","lowerLimit":"0.7","upperLimit":"1.0"}]}]},{"title":"Alp2N","categories":[{"measurements":[{"groupId":"OG000","value":"49.2","lowerLimit":"32.4","upperLimit":"74.7"},{"groupId":"OG001","value":"51.2","lowerLimit":"37.9","upperLimit":"69.2"},{"groupId":"OG002","value":"0.8","lowerLimit":"0.7","upperLimit":"1.0"},{"groupId":"OG003","value":"1.0","lowerLimit":"0.7","upperLimit":"1.3"}]}]},{"title":"AlpCN","categories":[{"measurements":[{"groupId":"OG000","value":"45.5","lowerLimit":"32.0","upperLimit":"64.7"},{"groupId":"OG001","value":"43.4","lowerLimit":"33.2","upperLimit":"56.7"},{"groupId":"OG002","value":"0.8","lowerLimit":"0.7","upperLimit":"1.0"},{"groupId":"OG003","value":"0.9","lowerLimit":"0.7","upperLimit":"1.1"}]}]},{"title":"RibN","categories":[{"measurements":[{"groupId":"OG000","value":"23.1","lowerLimit":"15.1","upperLimit":"35.2"},{"groupId":"OG001","value":"30.3","lowerLimit":"20.7","upperLimit":"44.3"},{"groupId":"OG002","value":"0.8","lowerLimit":"0.6","upperLimit":"1.1"},{"groupId":"OG003","value":"0.9","lowerLimit":"0.7","upperLimit":"1.1"}]}]}]},{"type":"SECONDARY","title":"Proportion of Mothers Achieving Vaccine Specific IgG Antibody Concentrations","description":"Proportion of mothers achieving vaccine specific IgG antibody concentrations in maternal samples respectively, above pre-defined arbitrary thresholds (0.5, 1, 2 μg/mL).","populationDescription":"Maternal immunogenicity analysis set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of mothers","timeFrame":"At delivery","groups":[{"id":"OG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"15"}]}],"classes":[{"title":"Alp1N >0.5","categories":[{"measurements":[{"groupId":"OG000","value":"98.0","lowerLimit":"89.5","upperLimit":"99.7"},{"groupId":"OG001","value":"100","lowerLimit":"93.5","upperLimit":"100"},{"groupId":"OG002","value":"14.3","lowerLimit":"4.0","upperLimit":"39.9"},{"groupId":"OG003","value":"13.3","lowerLimit":"3.7","upperLimit":"37.9"}]}]},{"title":"Alp1N >1","categories":[{"measurements":[{"groupId":"OG000","value":"96.0","lowerLimit":"86.5","upperLimit":"98.9"},{"groupId":"OG001","value":"98.2","lowerLimit":"90.4","upperLimit":"99.7"},{"groupId":"OG002","value":"7.1","lowerLimit":"1.3","upperLimit":"31.5"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Alp1N >2","categories":[{"measurements":[{"groupId":"OG000","value":"82.0","lowerLimit":"69.2","upperLimit":"90.2"},{"groupId":"OG001","value":"92.7","lowerLimit":"82.7","upperLimit":"97.1"},{"groupId":"OG002","value":"7.1","lowerLimit":"1.3","upperLimit":"31.5"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Alp2N >0.5","categories":[{"measurements":[{"groupId":"OG000","value":"98.0","lowerLimit":"89.3","upperLimit":"99.6"},{"groupId":"OG001","value":"100","lowerLimit":"93.1","upperLimit":"100"},{"groupId":"OG002","value":"7.7","lowerLimit":"1.4","upperLimit":"33.3"},{"groupId":"OG003","value":"7.1","lowerLimit":"1.3","upperLimit":"31.5"}]}]},{"title":"Alp2N >1","categories":[{"measurements":[{"groupId":"OG000","value":"91.8","lowerLimit":"80.8","upperLimit":"96.8"},{"groupId":"OG001","value":"90.4","lowerLimit":"79.4","upperLimit":"95.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Alp2N >2","categories":[{"measurements":[{"groupId":"OG000","value":"83.7","lowerLimit":"71.0","upperLimit":"91.5"},{"groupId":"OG001","value":"75.0","lowerLimit":"61.8","upperLimit":"84.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"AlpCN >0.5","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"92.9","upperLimit":"100"},{"groupId":"OG001","value":"98.2","lowerLimit":"90.4","upperLimit":"99.7"},{"groupId":"OG002","value":"7.1","lowerLimit":"1.3","upperLimit":"31.5"},{"groupId":"OG003","value":"21.4","lowerLimit":"7.6","upperLimit":"47.6"}]}]},{"title":"AlpCN >1","categories":[{"measurements":[{"groupId":"OG000","value":"92.0","lowerLimit":"81.2","upperLimit":"96.9"},{"groupId":"OG001","value":"94.6","lowerLimit":"85.2","upperLimit":"98.1"},{"groupId":"OG002","value":"7.1","lowerLimit":"1.3","upperLimit":"31.5"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"AlpCN >2","categories":[{"measurements":[{"groupId":"OG000","value":"84.0","lowerLimit":"71.5","upperLimit":"91.7"},{"groupId":"OG001","value":"89.1","lowerLimit":"78.2","upperLimit":"94.9"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"RibN >0.5","categories":[{"measurements":[{"groupId":"OG000","value":"87.2","lowerLimit":"74.8","upperLimit":"94.0"},{"groupId":"OG001","value":"88.5","lowerLimit":"77.0","upperLimit":"94.6"},{"groupId":"OG002","value":"7.1","lowerLimit":"1.3","upperLimit":"31.5"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"RibN >1","categories":[{"measurements":[{"groupId":"OG000","value":"76.6","lowerLimit":"62.8","upperLimit":"86.4"},{"groupId":"OG001","value":"76.9","lowerLimit":"63.9","upperLimit":"86.3"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"RibN >2","categories":[{"measurements":[{"groupId":"OG000","value":"63.8","lowerLimit":"49.5","upperLimit":"76.0"},{"groupId":"OG001","value":"63.5","lowerLimit":"49.9","upperLimit":"75.2"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]}]},{"type":"SECONDARY","title":"Proportion of Newborn Babies Achieving Vaccine Specific IgG Antibody Concentrations","description":"Proportion of newborn babies achieving vaccine specific IgG antibody concentrations above pre-defined arbitrary thresholds (0.5, 1, 2 μg/mL).","populationDescription":"Baby immunogenicity set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of newborns babies","timeFrame":"At birth","groups":[{"id":"OG000","title":"Babies From Women Vaccinated With GBS-NN/NN2 Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart.\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG001","title":"Babies From Women Vaccinated With GBS-NN/NN2 Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant."},{"id":"OG002","title":"Placebo Comparator: Babies From Women Living With HIV","description":"Babies from pregnant women living with HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%"},{"id":"OG003","title":"Placebo Comparator: Babies From Women Who do Not Have HIV","description":"Babies from pregnant women who do not have HIV who had:\n\n2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"11"}]}],"classes":[{"title":"Alp1N >0.5","categories":[{"measurements":[{"groupId":"OG000","value":"92.0","lowerLimit":"75.0","upperLimit":"97.8"},{"groupId":"OG001","value":"80.7","lowerLimit":"63.7","upperLimit":"90.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Alp1N >1","categories":[{"measurements":[{"groupId":"OG000","value":"84.0","lowerLimit":"65.4","upperLimit":"93.6"},{"groupId":"OG001","value":"77.4","lowerLimit":"60.2","upperLimit":"88.6"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Alp1N >2","categories":[{"measurements":[{"groupId":"OG000","value":"64.0","lowerLimit":"44.5","upperLimit":"79.8"},{"groupId":"OG001","value":"64.5","lowerLimit":"47.0","upperLimit":"78.9"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Alp2N >0.5","categories":[{"measurements":[{"groupId":"OG000","value":"82.6","lowerLimit":"62.9","upperLimit":"93.0"},{"groupId":"OG001","value":"75.9","lowerLimit":"57.9","upperLimit":"87.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Alp2N >1","categories":[{"measurements":[{"groupId":"OG000","value":"73.9","lowerLimit":"53.5","upperLimit":"87.5"},{"groupId":"OG001","value":"72.4","lowerLimit":"54.3","upperLimit":"85.3"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Alp2N >2","categories":[{"measurements":[{"groupId":"OG000","value":"56.5","lowerLimit":"36.8","upperLimit":"74.4"},{"groupId":"OG001","value":"55.2","lowerLimit":"37.6","upperLimit":"71.6"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"AlpCN >0.5","categories":[{"measurements":[{"groupId":"OG000","value":"81.8","lowerLimit":"61.5","upperLimit":"92.7"},{"groupId":"OG001","value":"75.9","lowerLimit":"57.9","upperLimit":"87.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"10.0","lowerLimit":"1.8","upperLimit":"40.4"}]}]},{"title":"AlpCN >1","categories":[{"measurements":[{"groupId":"OG000","value":"68.2","lowerLimit":"47.3","upperLimit":"83.6"},{"groupId":"OG001","value":"75.9","lowerLimit":"57.9","upperLimit":"87.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"AlpCN >2","categories":[{"measurements":[{"groupId":"OG000","value":"54.6","lowerLimit":"34.7","upperLimit":"73.1"},{"groupId":"OG001","value":"69.0","lowerLimit":"50.8","upperLimit":"82.7"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"RibN >1","categories":[{"measurements":[{"groupId":"OG000","value":"64.0","lowerLimit":"44.5","upperLimit":"79.8"},{"groupId":"OG001","value":"66.7","lowerLimit":"48.8","upperLimit":"80.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"RibN >0.5","categories":[{"measurements":[{"groupId":"OG000","value":"72.0","lowerLimit":"52.4","upperLimit":"85.7"},{"groupId":"OG001","value":"76.7","lowerLimit":"59.1","upperLimit":"88.2"},{"groupId":"OG002","value":"16.7","lowerLimit":"3.0","upperLimit":"56.4"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"RibN >2","categories":[{"measurements":[{"groupId":"OG000","value":"48.0","lowerLimit":"30.0","upperLimit":"66.5"},{"groupId":"OG001","value":"56.7","lowerLimit":"39.2","upperLimit":"72.6"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"All adverse events were collected from informed consent signature (Between 24- and 28-weeks of gestation) until end of study (Visit 10: 365±8 day after birth), up to 69 weeks from signing of informed consent form. Maternal Serious Adverse Events (SAEs) will be reported from the day of signing informed consent for study participation to 28 days post-delivery (Visit 6).","eventGroups":[{"id":"EG000","title":"GBS-NN/NN2 in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant.","deathsNumAffected":0,"deathsNumAtRisk":80,"seriousNumAffected":29,"seriousNumAtRisk":80,"otherNumAffected":62,"otherNumAtRisk":80},{"id":"EG001","title":"GBS-NN/NN2 in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV\n\nGBS-NN/NN2: GBS-NN/NN2 bound to Alhydrogel as an adjuvant.","deathsNumAffected":0,"deathsNumAtRisk":80,"seriousNumAffected":23,"seriousNumAtRisk":80,"otherNumAffected":61,"otherNumAtRisk":80},{"id":"EG002","title":"Placebo Comparator in Pregnant Women Living With HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV\n\nPlacebo: Normal Saline 0.9%","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":7,"seriousNumAtRisk":20,"otherNumAffected":14,"otherNumAtRisk":20},{"id":"EG003","title":"Placebo Comparator in Pregnant Women Who do Not Have HIV","description":"2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV\n\nPlacebo: Normal Saline 0.9%","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":6,"seriousNumAtRisk":20,"otherNumAffected":15,"otherNumAtRisk":20}],"seriousEvents":[{"term":"Fœtal distress syndrome","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":80},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":80},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Pre-eclampsia","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Premature delivery","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Premature rupture of membranes","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Preterm premature rupture of membranes","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Oligohydramnios","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Prolonged labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Failed induction of labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Gestational hypertension","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"HELLP syndrome","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Anembryonic gestation","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Face presentation","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Foetal malposition","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Haemorrhage in pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Obstructed labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Premature labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Premature separation of placenta","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Prolonged pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Retained products of conception","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Uterine contractions during pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Cephalo-pelvic disproportion","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Foetal death","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Cervicitis","organSystem":"Infections and infestations","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Postpartum sepsis","organSystem":"Infections and infestations","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Brief psychotic disorder with postpartum onset","organSystem":"Psychiatric disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Arterial ligation","organSystem":"Surgical and medical procedures","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]}],"otherEvents":[{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":25,"numAtRisk":80},{"groupId":"EG001","numEvents":20,"numAffected":16,"numAtRisk":80},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":20},{"groupId":"EG003","numEvents":8,"numAffected":5,"numAtRisk":20}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":80},{"groupId":"EG001","numEvents":17,"numAffected":13,"numAtRisk":80},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":20}]},{"term":"Vulvovaginal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":80},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":80},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Malaria","organSystem":"Infections and infestations","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":80},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":80},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":20}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Gastroesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":80},{"groupId":"EG001","numEvents":25,"numAffected":17,"numAtRisk":80},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":20},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":80},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":80},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":80},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":80},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":20}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":80},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":80},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"ATC Hierarchy 2023","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":80},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":80},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":20}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Cornelia Oostvogels/Chief Medical Officer (CMO)","organization":"MinervaX","email":"lio@minervax.com","phone":"00491515092821"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-01-29","uploadDate":"2026-02-12T10:37","filename":"Prot_000.pdf","size":755182},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-06-02","uploadDate":"2026-02-12T10:38","filename":"SAP_001.pdf","size":2822429}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D013290","term":"Streptococcal Infections"}],"ancestors":[{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}